GlassScriptPhysician profile
Gregory D Kaczmarek
NPI 1629032958
$19,866.25
in general payments reported to CMS, 2019-2025
72 companies · $2,541 in 2025
The $2,541 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,728 · 2020: $2,336 · 2021: $3,229 · 2022: $3,089 · 2023: $2,976 · 2024: $2,969 · 2025: $2,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,454 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,453.55 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,791.57 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $2,223.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,064.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,010.47 | 2019-2025 | |
| Amgen INC. | $1,336.01 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $1,054.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $713.86 | 2020-2025 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $624.76 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $576.17 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $496.07 | 2020-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.52 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $300.50 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $268.18 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $249.52 | 2019-2023 | Myrbetriq |
| Ultragenyx Pharmaceutical INC. | $240.48 | 2020-2023 | Crysvita |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Kaczmarek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.